| 2.27 0.57 (33.53%) | 07-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.75 |
1-year : | 3.22 |
| Resists | First : | 2.36 |
Second : | 2.75 |
| Pivot price | 1.63 |
|||
| Supports | First : | 1.81 |
Second : | 1.48 |
| MAs | MA(5) : | 1.75 |
MA(20) : | 1.67 |
| MA(100) : | 1.7 |
MA(250) : | 2.41  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.9 |
D(3) : | 46.1 |
| RSI | RSI(14): 74.3 |
|||
| 52-week | High : | 4.92 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CMMB ] has closed Bollinger Bands are 55.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.37 - 2.37 | 2.37 - 2.38 |
| Low: | 1.73 - 1.74 | 1.74 - 1.75 |
| Close: | 2.25 - 2.27 | 2.27 - 2.28 |
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Fri, 03 Jul 2026
CMMB - Chemomab Therapeutics Ltd ADR Latest SEC Filings - Finviz
Thu, 02 Jul 2026
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Sun, 28 Jun 2026
Enterprise value to revenue forward of Chemomab Therapeutics Ltd. – NASDAQ:CMMB - TradingView
Fri, 26 Jun 2026
Chemomab Therapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:CMMB) - TradingView
Wed, 17 Jun 2026
Chemomab Therapeutics Ltd - TradingKey
Tue, 02 Jun 2026
Chemomab Therapeutics (CMMB) reshapes board and audit committee leadership - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 4.8 (%) |
| Shares Short | 134 (K) |
| Shares Short P.Month | 40 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.3 % |
| Return on Equity (ttm) | -70.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.03 |
| PEG Ratio | 0 |
| Price to Book value | 1.52 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|